Nature of Update
This is a regulatory compliance filing under SEBI Regulation 30 regarding the incorporation of a wholly owned subsidiary.
Target Entity
Warren Lifesciences Private Limited
Type of Deal
Incorporation of 100% wholly owned subsidiary
Stake/Capacity
100% shareholding acquired through subscription of 10,000 equity shares
Deal Value
₹100,000 total investment (10,000 shares at ₹10 face value each)
Funding Source
Cash consideration
Financial Impact
Not disclosed beyond the initial capital investment of ₹100,000. The subsidiary is newly incorporated and has not commenced business operations.
Timeline
Incorporated on 26th September, 2026. No specific timeline provided for business commencement.
Strategic Rationale
WLPL is incorporated with the object to manufacture, develop, sell etc. pharmaceutical products including but not limited to active pharmaceutical ingredients, finished formulations, key starting materials. The business aligns with Indoco Remedies' main line of business in the pharmaceutical sector.
Approval Status
Approved by the Committee of Executive Director as per previous intimation dated 18th September, 2026. The subsidiary has been formally incorporated on 26th September, 2026.
Related Party Status
WLPL is a related party of Indoco Remedies Limited as it is a wholly owned subsidiary.